ERBB2 and breast cancer: Denkert divided BC patients into three groups according to sTILs infiltration in tumor tissues: low sTILs infiltration (0–10%), medium sTILs infiltration (11–59%) and high sTILs infiltration (60–100%), their studies suggested that high sTILs infiltration can predict the NAC response of all BC subtypes and is correlated with the survival benefit of Her2-positive BC and triple-negative breast cancer (TNBC) (14).